Bicara Therapeutics (BCAX) Other Working Capital Changes (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Other Working Capital Changes of -$270000.0 for Q1 2026, down 83.67% year-over-year from -$1.7 million in Q1 2025, and up 7.53% quarter-over-quarter from -$292000.0 in Q4 2025.
Powered by 
Analysis
Bicara Therapeutics (BCAX) Other Working Capital Changes (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Other Working Capital Changes history runs 4 years deep, the most recent figure standing at -$270000.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 83.67% year-over-year to -$270000.0; the TTM figure through Mar 2026 stood at -$1.1 million (down 52850.0% YoY), while the FY2025 annual figure was -$932000.0, down 1250.62% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at -$270000.0, up from -$292000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $16.6 million in Q4 2024, with the low at -$4.1 million in Q1 2025.
- The 4-year median for Other Working Capital Changes is -$2000.0 (2023), against an average of $953900.0.
- The sharpest annual moves came in 2024 and 2025: Other Working Capital Changes jumped 830.0% in 2024, then tumbled 340.28% in 2025.
- Bicara Therapeutics' Other Working Capital Changes stood at -$40000.0 in 2023, then surged by 830.0% to $292000.0 in 2024, then slumped by 200.0% to -$292000.0 in 2025, then grew by 7.53% to -$270000.0 in 2026.
- Business Quant data shows BCAX's Other Working Capital Changes at -$270000.0 in Q1 2026, -$292000.0 in Q4 2025, and -$317000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Bicara Therapeutics | 1.57 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.40 Mn |
| Jun 30, 2026 | 1.40 Mn |
| Mar 31, 2026 | -2.09 Mn |
| Mar 31, 2026 | -2.09 Mn |
| Dec 31, 2025 | -839,000.00 |
| Dec 31, 2025 | -839,000.00 |
| Sep 30, 2025 | 301,000.00 |
| Sep 30, 2025 | 301,000.00 |
| Jun 30, 2025 | -627,000.00 |
| Jun 30, 2025 | -627,000.00 |
| Mar 31, 2025 | -4.12 Mn |
| Mar 31, 2025 | -4.12 Mn |
| Dec 31, 2024 | 16.57 Mn |
| Dec 31, 2024 | 16.57 Mn |
| Sep 30, 2024 | 108,000.00 |
| Sep 30, 2024 | 108,000.00 |
| Jun 30, 2024 | -63,000.00 |
| Jun 30, 2024 | -63,000.00 |
| Mar 31, 2024 | 235,000.00 |
| Mar 31, 2024 | 235,000.00 |